Laquinimod-d5

• Product Name Alternative:

  ABR-215062-d5

• UNSPSC Description:

  Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1].

• Target Antigen:

  Apoptosis; Isotope-Labeled Compounds; NF-κB

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Apoptosis;NF-κB;Others

• Field of Research:

  Inflammation/Immunology

• Purity:

  98.25

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  [2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]

• Molecular Weight:

  361.83

• References & Citations:

  [1]Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec;262 Pt A:66-71.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1214267-09-0